Cancer immunotherapy
Alemany’s & Piulats’s lab

DESCRIPTION

Our main aim is to develop new anticancer treatments based on novel designs of oncolytic adenoviruses, combining them with mesenchymal stem cells and cellular therapies derived from tumor reactive T-lymphocytes against solid tumors.

The Cancer Immunotherapy group, led by Dr Piulats and Dr Alemany, is dedicated to develop new immunotherapies based on oncolytic adenoviruses or advanced therapy medicinal products (ATMPs) to treat the so-called “cold” tumors and rare malignancies. Oncolytic viruses represent a double antitumor strategy: they have an oncolytic activity and on top of that, they promote lymphocyte infiltration and immune responses against tumors. We are designing and evaluating new oncolytic adenovirus to improve their Intratumor diffusion and tumor reactivity and testing those using murine models. We are developing CAR-NK cells models, cell therapies based on autoreactive TCRs from patients and combined ATMP using virus and mesenchymal stem cells. We combine clinical and translational research, and we have led different clinical trials based on immunotherapy, demonstrating the feasibility of immunotherapy approaches to treat this kind of tumors.

Group members

Ramón Alemany Bonastre

Group leaders

Josep Maria Piulats Rodríguez

Group leaders

Publications

SWI/SNF Complex Alterations in Tumors with Rhabdoid Features: Novel Therapeutic Approaches and Opportunities for Adoptive Cell Therapy

14 de July de 2023/in Alemany’s & Piulats’s lab/by

Int J Mol Sci. 2023 Jul 6;24(13):11143. doi: 10.3390/ijms241311143. ABSTRACT The SWItch/Sucrose Non-Fermentable (SWI/SNF) chromatin-remodeling complex is one of the most remarkably altered epigenetic regulators in cancer. Pathogenic mutations in genes encoding SWI/SNF-related proteins have been recently described in many solid tumors, including rare and aggressive malignancies with rhabdoid features with no standard therapies in […]

MBD4-associated neoplasia syndrome: screening of cases with suggestive phenotypes

4 de July de 2023/in Alemany’s & Piulats’s lab/by

Eur J Hum Genet. 2023 Oct;31(10):1185-1189. doi: 10.1038/s41431-023-01418-5. Epub 2023 Jul 4. ABSTRACT Germline mutations in MBD4, which, like MUTYH and NTHL1, encodes a glycosylase of the DNA based excision repair system, cause an autosomal recessive syndrome characterised by increased risk of acute myeloid leukaemia, gastrointestinal polyposis, colorectal cancer (CRC) and, to a lesser extent, […]

Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study

5 de June de 2023/in Alemany’s & Piulats’s lab/by

Eur Urol. 2023 Sep;84(3):321-330. doi: 10.1016/j.eururo.2023.05.021. Epub 2023 Jun 3. ABSTRACT BACKGROUND: Initial TRITON2 (NCT02952534) results demonstrated the efficacy of rucaparib 600 mg BID in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with a BRCA1 or BRCA2 (BRCA) or other DNA damage repair (DDR) gene alteration. OBJECTIVE: To present the final data from TRITON2. […]

Differences in glucose metabolic activity in liver metastasis separates two groups of metastatic uveal melanoma patients with different prognosis

22 de May de 2023/in Alemany’s & Piulats’s lab/by

Cancer Med. 2023 Jul;12(13):14062-14071. doi: 10.1002/cam4.6058. Epub 2023 May 21. ABSTRACT BACKGROUND: Uveal melanoma metastasizes to the liver. We aimed to explore the metabolic activity of liver metastases (LM) as a biomarker for survival. METHODS: We analyzed newly diagnosed patients with metastatic UM (MUM) with LM detected by liver-directed imaging and had undergone a PET/CT […]

A hotspot for posttranslational modifications on the androgen receptor dimer interface drives pathology and anti-androgen resistance

15 de March de 2023/in Alemany’s & Piulats’s lab/by

Sci Adv. 2023 Mar 17;9(11):eade2175. doi: 10.1126/sciadv.ade2175. Epub 2023 Mar 15. ABSTRACT Mutations of the androgen receptor (AR) associated with prostate cancer and androgen insensitivity syndrome may profoundly influence its structure, protein interaction network, and binding to chromatin, resulting in altered transcription signatures and drug responses. Current structural information fails to explain the effect of […]

Research Projects

Name: Dr Ramón Alemany Bonastre
Role: Group leader (coPI)

Name: Dr Josep Maria Piulats Rodríguez, MD
Role: Group leader (coPI)

Name: Dr Rafael Moreno Olié
Role: Principal Investigator

Name: Dr María Dolores López Robles
Role: Postdoctoral researcher

Name: Dr Marcel Costa García
Role: Postdoctoral Researcher

Name: Dr Gabriel Espinosa Carrasco
Role: Postdoctoral researcher

Name: Sílvia Torres Manjón
Role: Lab manager

Name: Laura Moya Borrrego
Role: Predoctoral Researcher

Name: Pau Fiol Mata
Role: Predoctoral Researcher

Name: Luís Paul del Carpio Huerta, MD
Role: Predoctoral Researcher (Rio Ortega contract)

Name: Juan Antonio Marín Jiménez, MD
Role: Predoctoral Researcher (La Caixa- Inphinit Retaining)

Name: Sebastián Ciro Carné Martín
Role: Predoctoral Researcher

Name: Ainhoa Muñoz Metrino
Role: Technician

Name: Dr Carles Codony Servat
Role: Project manager

Collaborations

Dr Alemany has published 129 articles, several book chapters and 16 patents (5 in the exploitation phase) in the field of therapeutic use of adenoviruses as gene vectors or oncolytic viruses. Editor of the journals “Gene Therapy” “Cancer Gene Therapy” and “Human Gene Therapy”, President of the Spanish Society of Gene and Cellular Therapy from 2016 to 2018, and advisor to several biotech companies that develop oncolytic viruses (ORCA Therapeutics, Oncolytics Biotech, Sagetis). In 2009 he co-founded the company VCN Biosciences. GHe collaborates among othersc with: Cristina Fillat Fonts, IDIBAPS; Juan José Rojas Expósito, IDIBELL; Javier García Castro, ISCIII , Madrid; Manuel Ramírez Orellana, Hosp Niño Jesús, Madrid; Alena Gros Vidal, VHIO; Sonia Guedan Carrió, IDIBAPS.

Dr Piulats is chair for Uveal Melanoma in the Spanish Melanoma group. He is part of the IRCI (International Rare Cancer Initiative) and EURACAN for rare melanoma and rare cutaneous tumors. He collaborates with Dr Alvaro Aytes (Idibell) and Dr Himisha Beltran (Dana Farber) in prostate cancer (projects Fundación Mútua Madrileña and DoD Prostate Cancer) and with Dr Xavier Matías-Guiu and Dr Alena Gros in Gynecologic tumors (La MaratóTV3, Immune4all in Ayudas de Proyectos de Investigación de Medicina Personalizada de Precisión). He collaborates with Dr Moreno (ICO-Idibell) and Dr África González Murillo (Hospital Universitario del Niño Jesús) in the PULSE-UM clinical study and with Dr Juan Marín Liberal (ICO), Drs Alena Gros, Elena Garralda (VHIO), Dr Sergi Querol (Banc de sang i Teixits) and Dr Jesús García-Donas Jiménez (Centro Integral Oncológico Clara Campal) (Proyectos Clinica Independiente – ISCIII).

Presently Dr Piulats has begun a collaboration asking for new funding for novel treatments in metastatic uveal melanoma with Alena Gros (VHIO), Gal Cafri and Yochai Wolf from Sheba Research Institute in Israel and Udai Kammula from UPMC in USA.

Dr Moreno collaborates in the development of NK-CAR cells with Dr Ana Sureda (ICO). He also collaborates with Dr. Marta Alonso (CIMA-University of Navarra) in the development towards a protocol and clinical application for GBM.

Cancer immunotherapy Alemany’s & Piulats’s lab

DESCRIPTION

Ramón Alemany Bonastre

Group leaders

Josep Maria Piulats Rodríguez

Group leaders

Rafael Moreno Olié

Researchers

María Dolores López Robles

Researchers

Gabriel Espinosa Carrasco

Researchers

Marcel Costa García

Researchers

Luís Paul del Carpio Huerta

Researchers

Juan Antonio Marín Jiménez

Young investigators

Laura Moya Borrego

Young investigators

Pau Fiol Mata

Young investigators

Sebastián Ciro Carné Martín

Young investigators

Silvia Torres Manjón

Support staff

Ainhoa Muñoz Metrino

Support staff

Carles Codony Servat

Support staff

CONTACT US

Cancer immunotherapy
Alemany’s & Piulats’s lab